May 22, 2024 10:41 AM EDT
News Briefing

Dyne's $305M of­fer­ing; Nanobi­otix de­lays Ph2 read­out

ENDPOINTS

Dyne Ther­a­peu­tics ex­pects to net $305M in stock sale: The com­pa­ny on Mon­day dropped up­dat­ed stock-mov­ing re­sults for its my­oton­ic dy­s­tro­phy type …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times